Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

CMIP is a negative regulator of T cell signaling.

Oniszczuk J, Sendeyo K, Chhuon C, Savas B, Cogné E, Vachin P, Henique C, Guerrera IC, Astarita G, Frontera V, Pawlak A, Audard V, Sahali D, Ollero M.

Cell Mol Immunol. 2019 Aug 8. doi: 10.1038/s41423-019-0266-5. [Epub ahead of print]

PMID:
31395948
2.

Cationic poly(cyclodextrin)/alginate nanocapsules: From design to application as efficient delivery vehicle of 4-hydroxy tamoxifen to podocyte in vitro.

Belbekhouche S, Oniszczuk J, Pawlak A, El Joukhar I, Goffin A, Varrault G, Sahali D, Carbonnier B.

Colloids Surf B Biointerfaces. 2019 Jul 1;179:128-135. doi: 10.1016/j.colsurfb.2019.03.060. Epub 2019 Mar 28.

PMID:
30954013
3.

Kidney Lipidomics by Mass Spectrometry Imaging: A Focus on the Glomerulus.

Abbas I, Noun M, Touboul D, Sahali D, Brunelle A, Ollero M.

Int J Mol Sci. 2019 Apr 1;20(7). pii: E1623. doi: 10.3390/ijms20071623. Review.

4.

Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: a retrospective study of 8 cases.

Arrestier R, Satie AP, Zhang SY, Plaisier E, Isnard-Bagnis C, Gatault P, Raimbourg Q, Buob D, Vocila F, Heng AE, Francois H, Moktefi A, Canaud G, Matignon M, Dejucq-Rainsford N, Brocheriou I, Sahali D, Audard V.

BMC Nephrol. 2018 Nov 20;19(1):331. doi: 10.1186/s12882-018-1132-x.

5.

Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis.

Bouachi K, Moktefi A, Zhang SY, Oniszczuk J, Sendeyo K, Remy P, Audard V, Pawlak A, Ollero M, Sahali D.

PLoS One. 2018 Nov 15;13(11):e0207066. doi: 10.1371/journal.pone.0207066. eCollection 2018.

6.

Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring.

Leibler C, Moktefi A, Matignon M, Debiais-Delpech C, Oniszczuk J, Sahali D, Cohen JL, Grimbert P, Audard V.

J Clin Med. 2018 Nov 9;7(11). pii: E430. doi: 10.3390/jcm7110430.

7.

An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).

Rémy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, Vigneau C, Bouachi K, Dantal J, Vrigneaud L, Karras A, Pourcine F, Gatault P, Grimbert P, Ait Sahlia N, Moktefi A, Daugas E, Rigothier C, Bastuji-Garin S, Sahali D; MSN Trial Investigators.

Kidney Int. 2018 Dec;94(6):1217-1226. doi: 10.1016/j.kint.2018.07.021. Epub 2018 Oct 29.

PMID:
30385039
8.

NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D.

J Autoimmun. 2018 Mar;88:91-102. doi: 10.1016/j.jaut.2017.10.006. Epub 2017 Oct 19.

PMID:
29056249
9.

Nephrotic Syndrome in Small Cell Lung Cancer and Induction of C-Mip in Podocytes.

Bouatou Y, Koessler T, Oniszczuk J, Zhang SY, Moll S, Audard V, de Seigneux S, Sahali D.

Am J Kidney Dis. 2017 Mar;69(3):477-480. doi: 10.1053/j.ajkd.2016.09.026. Epub 2017 Jan 4.

PMID:
28063735
10.

Repression of CMIP transcription by WT1 is relevant to podocyte health.

Moktefi A, Zhang SY, Vachin P, Ory V, Henique C, Audard V, Rucker-Martin C, Gouadon E, Eccles M, Schedl A, Heidet L, Ollero M, Sahali D, Pawlak A.

Kidney Int. 2016 Dec;90(6):1298-1311. doi: 10.1016/j.kint.2016.07.016. Epub 2016 Sep 17.

PMID:
27650733
11.

Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients.

Nielsen L, Canouï-Poitrine F, Jais JP, Dahmane D, Bartolucci P, Bentaarit B, Gellen-Dautremer J, Remy P, Kofman T, Matignon M, Suberbielle C, Jacquelinet C, Wagner-Ballon O, Sahali D, Lang P, Damy T, Galactéros F, Grimbert P, Habibi A, Audard V.

Br J Haematol. 2016 Jul;174(1):148-52. doi: 10.1111/bjh.14040. Epub 2016 Mar 17.

PMID:
26992059
12.

Successful Treatment of Lung Calciphylaxis With Sodium Thiosulfate in a Patient With Sickle Cell Disease: A Case Report.

Arrestier R, Dudreuilh C, Remy P, Boulahia G, Bentaarit B, Leibler C, Adedjouma A, Kofman T, Matignon M, Sahali D, Dufresne R, Deux JF, Colin C, Grimbert P, Lang P, Bartolucci P, Maitre B, Tran Van Nhieu J, Audard V.

Medicine (Baltimore). 2016 Feb;95(6):e2768. doi: 10.1097/MD.0000000000002768.

13.

Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease.

Bartolucci P, Habibi A, Stehlé T, Di Liberto G, Rakotoson MG, Gellen-Dautremer J, Loric S, Moutereau S, Sahali D, Wagner-Ballon O, Remy P, Lang P, Grimbert P, Audureau E, Godeau B, Galacteros F, Audard V.

J Am Soc Nephrol. 2016 Jun;27(6):1847-53. doi: 10.1681/ASN.2014111126. Epub 2015 Nov 19.

14.

Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases.

Dauvergne M, Moktefi A, Rabant M, Vigneau C, Kofman T, Burtey S, Corpechot C, Stehlé T, Desvaux D, Rioux-Leclercq N, Rouvier P, Knebelmann B, Boffa JJ, Frouget T, Daugas E, Jablonski M, Dahan K, Brocheriou I, Remy P, Grimbert P, Lang P, Chazouilleres O, Sahali D, Audard V.

Medicine (Baltimore). 2015 Jul;94(30):e1243. doi: 10.1097/MD.0000000000001243.

15.

Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.

Kofman T, Zhang SY, Copie-Bergman C, Moktefi A, Raimbourg Q, Francois H, Karras A, Plaisier E, Painchart B, Favre G, Bertrand D, Gyan E, Souid M, Roos-Weil D, Desvaux D, Grimbert P, Haioun C, Lang P, Sahali D, Audard V.

Medicine (Baltimore). 2014 Nov;93(24):350-8. doi: 10.1097/MD.0000000000000206. Erratum in: Medicine (Baltimore). 2014 Nov;93(24):414.

16.

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC.

Medicine (Baltimore). 2014 Nov;93(24):333-9. doi: 10.1097/MD.0000000000000207. Erratum in: Medicine (Baltimore). 2014 Nov;93(24):414.

17.

Inhibition of the VEGF signalling pathway and glomerular disorders.

Ollero M, Sahali D.

Nephrol Dial Transplant. 2015 Sep;30(9):1449-55. doi: 10.1093/ndt/gfu368. Epub 2014 Dec 5. Review.

PMID:
25480873
18.

Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Sahali D, Sendeyo K, Mangier M, Audard V, Zhang SY, Lang P, Ollero M, Pawlak A.

Semin Immunopathol. 2014 Jul;36(4):421-9. doi: 10.1007/s00281-013-0415-3. Epub 2014 Jan 9. Review.

19.

Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.

Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D.

Kidney Int. 2014 Feb;85(2):457-70. doi: 10.1038/ki.2013.344. Epub 2013 Sep 25.

20.

Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study.

Stehlé T, Joly D, Vanhille P, Boffa JJ, Rémy P, Mesnard L, Hoffmann M, Grimbert P, Choukroun G, Vrtovsnik F, Verine J, Desvaux D, Walker F, Lang P, Mahevas M, Sahali D, Audard V.

Orphanet J Rare Dis. 2013 Apr 30;8:65. doi: 10.1186/1750-1172-8-65.

21.

Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy.

Sendeyo K, Audard V, Zhang SY, Fan Q, Bouachi K, Ollero M, Rucker-Martin C, Gouadon E, Desvaux D, Bridoux F, Guellaën G, Ronco P, Lang P, Pawlak A, Sahali D.

Kidney Int. 2013 Mar;83(3):414-25. doi: 10.1038/ki.2012.426. Epub 2013 Jan 9.

22.

[Kidney involvement in sarcoidosis].

Stehlé T, Boffa JJ, Lang P, Desvaux D, Sahali D, Audard V.

Rev Med Interne. 2013 Sep;34(9):538-44. doi: 10.1016/j.revmed.2012.10.009. Epub 2012 Nov 13. Review. French.

PMID:
23154110
23.

c-mip down-regulates NF-κB activity and promotes apoptosis in podocytes.

Ory V, Fan Q, Hamdaoui N, Zhang SY, Desvaux D, Audard V, Candelier M, Noel LH, Lang P, Guellaën G, Pawlak A, Sahali D.

Am J Pathol. 2012 Jun;180(6):2284-92. doi: 10.1016/j.ajpath.2012.02.008. Epub 2012 Apr 14.

24.

[Pathogenesis and treatment of idiopathic nephrotic syndrome in adults].

Sahali D, Audard V, Rémy P, Lang P.

Nephrol Ther. 2012 Jun;8(3):180-92. doi: 10.1016/j.nephro.2011.11.010. Epub 2012 Mar 16. Review. French.

PMID:
22425458
25.

Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation.

Audard V, Kamar N, Sahali D, Cardeau-Desangles I, Homs S, Remy P, Aouizerate J, Matignon M, Rostaing L, Lang P, Grimbert P.

Transpl Int. 2012 May;25(5):e62-6. doi: 10.1111/j.1432-2277.2012.01462.x. Epub 2012 Mar 13.

26.

Upregulation of nuclear factor-related kappa B suggests a disorder of transcriptional regulation in minimal change nephrotic syndrome.

Audard V, Pawlak A, Candelier M, Lang P, Sahali D.

PLoS One. 2012;7(1):e30523. doi: 10.1371/journal.pone.0030523. Epub 2012 Jan 23.

27.

Immunopathogenesis of idiopathic nephrotic syndrome.

Zhang SY, Audard V, Fan Q, Pawlak A, Lang P, Sahali D.

Contrib Nephrol. 2011;169:94-106. doi: 10.1159/000313947. Epub 2011 Jan 20. Review.

28.

Paradoxical embolism following thromboaspiration of an arteriovenous fistula thrombosis: a case report.

Bentaarit B, Duval AM, Maraval A, Dahmane D, Dahan K, Amara B, Lang P, Sahali D.

J Med Case Rep. 2010 Oct 28;4:345. doi: 10.1186/1752-1947-4-345.

29.

[Molecular mechanisms in nephrotic syndrome: role of c-mip in podocyte dysfunctions].

Zhang SY, Audard V, Lang P, Sahali D.

Med Sci (Paris). 2010 Jun-Jul;26(6-7):592-6. doi: 10.1051/medsci/2010266-7592. French. No abstract available.

30.

c-mip impairs podocyte proximal signaling and induces heavy proteinuria.

Zhang SY, Kamal M, Dahan K, Pawlak A, Ory V, Desvaux D, Audard V, Candelier M, BenMohamed F, Matignon M, Christov C, Decrouy X, Bernard V, Mangiapan G, Lang P, Guellaën G, Ronco P, Sahali D.

Sci Signal. 2010 May 18;3(122):ra39. doi: 10.1126/scisignal.2000678. Erratum in: Sci Signal. 2010;3(123):er7. Mohamed, Fatima Ben [corrected to BenMohamed, Fatima].

31.

Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes.

Audard V, Zhang SY, Copie-Bergman C, Rucker-Martin C, Ory V, Candelier M, Baia M, Lang P, Pawlak A, Sahali D.

Blood. 2010 May 6;115(18):3756-62. doi: 10.1182/blood-2009-11-251132. Epub 2010 Mar 3.

32.

C-mip interacts with the p85 subunit of PI3 kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase.

Kamal M, Pawlak A, BenMohamed F, Valanciuté A, Dahan K, Candelier M, Lang P, Guellaën G, Sahali D.

FEBS Lett. 2010 Feb 5;584(3):500-6. doi: 10.1016/j.febslet.2009.12.015. Epub 2009 Dec 16.

33.

[Recent advances in the pathophysiology of idiopathic nephrotic syndrome].

Audard V, Ory V, Zhang SY, Candelier M, Pawlak A, Lang P, Sahali D.

Arch Pediatr. 2009 Jun;16(6):793-5. doi: 10.1016/S0929-693X(09)74156-9. French. No abstract available.

PMID:
19541174
34.

Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation.

Bruneau S, Le Berre L, Hervé C, Valanciuté A, Kamal M, Naulet J, Tesson L, Foucher Y, Soulillou JP, Sahali D, Dantal J.

Am J Kidney Dis. 2009 Sep;54(3):522-32. doi: 10.1053/j.ajkd.2009.03.021. Epub 2009 Jun 10.

35.

Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.

Audard V, Matignon M, Weiss L, Remy P, Pardon A, Haioun C, Belhadj K, Salomon L, Hillon ML, Sahali D, Vermes E, Lang P, Grimbert P.

Am J Transplant. 2009 Jan;9(1):236-40. doi: 10.1111/j.1600-6143.2008.02469.x. Epub 2008 Nov 27.

36.

[Vascular and renal effects of anti-angiogenic therapy].

Halimi JM, Azizi M, Bobrie G, Bouché O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D.

Nephrol Ther. 2008 Dec;4(7):602-15. doi: 10.1016/j.nephro.2008.10.002. Epub 2008 Nov 21. French.

PMID:
19027389
37.

C-mip interacts physically with RelA and inhibits nuclear factor kappa B activity.

Kamal M, Valanciute A, Dahan K, Ory V, Pawlak A, Lang P, Guellaen G, Sahali D.

Mol Immunol. 2009 Feb;46(5):991-8. doi: 10.1016/j.molimm.2008.09.034. Epub 2008 Nov 18.

PMID:
19019440
38.

[Minimal change nephrotic syndrome : new insights into disease pathogenesis].

Audard V, Lang P, Sahali D.

Med Sci (Paris). 2008 Oct;24(10):853-8. doi: 10.1051/medsci/20082410853. Review. French.

39.

A 59-kD renal antigen as a new target for rapidly progressive glomerulonephritis.

Audard V, Hellmark T, El Karoui K, Noël LH, Pardon A, Desvaux D, Touchard G, Remy P, Lang P, Sahali D.

Am J Kidney Dis. 2007 May;49(5):710-6.

PMID:
17472855
40.

Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature.

Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O.

Kidney Int. 2006 Jun;69(12):2251-60. Epub 2006 May 3. Review.

41.

Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients.

Pardon A, Audard V, Caillard S, Moulin B, Desvaux D, Bentaarit B, Remy P, Sahali D, Roudot-Thoraval F, Lang P, Grimbert P.

Nephrol Dial Transplant. 2006 Apr;21(4):1053-9. Epub 2005 Dec 19.

PMID:
16364987
42.

Abnormal RNA processing and altered expression of serin-rich proteins in minimal-change nephrotic syndrome.

Grimbert P, Audard V, Valanciute A, Pawlak A, Lang P, Guellaën G, Sahali D.

Pediatr Res. 2005 Jan;57(1):133-7. Epub 2004 Nov 5.

PMID:
15531747
43.

The Filamin-A is a partner of Tc-mip, a new adapter protein involved in c-maf-dependent Th2 signaling pathway.

Grimbert P, Valanciute A, Audard V, Lang P, Guellaën G, Sahali D.

Mol Immunol. 2004 Mar;40(17):1257-61.

PMID:
15128042
44.

NF-kappa B p65 antagonizes IL-4 induction by c-maf in minimal change nephrotic syndrome.

Valanciuté A, le Gouvello S, Solhonne B, Pawlak A, Grimbert P, Lyonnet L, Hue S, Lang P, Remy P, Salomon R, Bensman A, Guellaën G, Sahali D.

J Immunol. 2004 Jan 1;172(1):688-98.

45.
46.

Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization.

Grimbert P, Valanciute A, Audard V, Pawlak A, Le gouvelo S, Lang P, Niaudet P, Bensman A, Guellaën G, Sahali D.

J Exp Med. 2003 Sep 1;198(5):797-807. Epub 2003 Aug 25.

47.

Recent approaches to the pathogenesis of minimal-change nephrotic syndrome.

Grimbert P, Audard V, Remy P, Lang P, Sahali D.

Nephrol Dial Transplant. 2003 Feb;18(2):245-8. Review. No abstract available.

PMID:
12543875
48.

[Recent approaches to the pathogenesis of minimal change nephrotic syndrome].

Audard V, Grimbert P, Valanciuté A, Lang P, Guellaën G, Sahali D.

Nephrologie. 2002;23(7):367-9. Review. French.

PMID:
12500423
49.

[New insights about immunopathology of lipoid nephrosis].

Sahali D, Lang P, Guellaen G, Bensman A.

Bull Acad Natl Med. 2002;186(3):683-90; discussion 690-3. Review. French.

PMID:
12412189
50.

A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening.

Sahali D, Pawlak A, Valanciuté A, Grimbert P, Lang P, Remy P, Bensman A, Guellaën G.

J Am Soc Nephrol. 2002 May;13(5):1238-47.

Supplemental Content

Loading ...
Support Center